ABL Bio closed down in the early 110,000 won range amid selling pressure in the KOSDAQ market on the 29th. There was an intraday attempt to rebound, but it failed to maintain the upward momentum, leading to an expanded decline.

According to the Korea Exchange, ABL Bio finished trading at 111,900 won, down 2,600 won (2.27%) from the previous trading day. The intraday high was recorded at 115,600 won, and the low at 108,500 won. The trading volume was 355,097 shares, with a transaction value of around 39.4 billion won, maintaining a market capitalization in the 6.2 trillion won range. Right after the market opened, it rose to the 115,000 won level, but selling volume gradually increased, creating a situation where investors must remain highly alert to the stock's price trends early in the week.

Recently, across the overall biotech sector, issues such as clinical results, expectations for technology exports, and the verification of profitability are simultaneously coming to the forefront, leading to an increasing trend of stock-specific volatility. ABL Bio, a novel drug development company based on bispecific antibodies, is also experiencing a phase where market expectations and realistic verification intersect regarding its R&D for anticancer drugs and treatments for degenerative brain diseases, causing its stock price to react sensitively. The market is continuously keeping a close eye on global clinical data and the progress of its key pipelines.

Compared to the strong upward trend that saw the stock hover above 250,000 won earlier this year, the current stock price temperature has cooled significantly. It is trading at lower levels compared to that time, continuing its correction phase. The market views future clinical schedules and progress regarding technology transfers as the key variables that will once again stimulate investment sentiment. On the other hand, there is also a perspective that if results fall short of expectations, the possibility of volatility expanding once again cannot be ruled out.

Among investors, attention is focusing on whether the early 100,000 won range can serve as a short-term support line. Given the inherently high price volatility of biotech stocks, analyses suggest that the stock's direction could shift significantly depending on changes in supply and demand.

[※ The information provided in this article is intended to convey general stock market news and is not a solicitation for investment. AI assistance was utilized in the writing of this article. The stock market can be accompanied by high volatility, and the responsibility for investments lies with the investor themselves.]